HPV extended genotyping gains traction

Published May 15, 2026 by The Daily Scout

- A Contemporary OB/GYN review argues that reporting individual HPV genotypes could let clinicians tailor cervical screening beyond a simple positive/negative result. - The authors say persistence of the same HPV type and ASCCP’s “equal management for equal risk” framework could be refined by extended genotyping data. - If adopted, labs may face more selective cytology triage and will need clearer reporting and staff education. (contemporaryobgyn.net)

Why it matters

1/ HPV testing has transformed cervical cancer screening, but a new review in Contemporary OB/GYN pushes for a big upgrade: extended genotyping. Instead of just "HPV positive" or "negative," labs would report specific genotypes like HPV-16 or 18. This lets doctors tailor follow-up care more precisely. 2/ Why does this matter? There are over 200 HPV types, but only about 14 are high-risk for cervical cancer. HPV-16 and 18 cause ~70% of cases worldwide, per WHO data. Most infections clear naturally within 1-2 years, but persistent high-risk types drive precancerous changes. Current tests lump them together—genotyping splits them out. 3/ The review, by Dr. Warner Huh (UAB) and colleagues, argues genotyping reveals risk nuances. For example, persistent HPV-16 signals higher danger than a one-off HPV-51 detection. This builds on ASCCP guidelines, which already emphasize "equal management for equal risk." Genotyping data could refine that further. 4/ Take persistence: If the same genotype shows up in repeat tests, cancer risk climbs. Huh's team notes studies showing women with persistent HPV-16 have 100-200x higher risk of CIN3+ (precancer) vs. cleared infections. A simple positive/negative misses this—genotyping tracks the exact type over time. 5/ Real-world example: BD Onclarity, an FDA-approved test, already reports 14 high-risk types individually. Roche's cobas HPV test does 12, grouping some. The review spotlights these as models. Clinicians could skip colposcopy for low-risk singles (e.g., HPV-53) but act fast on HPV-16/18 doubles. 6/ Labs aren't ready yet. Adoption means shifting from pooled results to granular reports. Huh et al. warn of challenges: selective cytology triage (only for certain types), clearer result formatting, and staff training. Poor implementation could confuse providers and delay care. 7/ Guidelines are key. ASCCP's 2019 update prioritizes risk-based management over rigid rules. Genotyping fits perfectly—e.g., 4% immediate colposcopy risk for HPV-16/18+ vs. 1% for others at same cytology level, per management consortium data. Future updates might mandate it. 8/ Evidence is building. A 2023 study in The Lancet Oncology found genotyping cut unnecessary colposcopies by 20-30% without missing cancers. Cost? Tests run $40-60 now; genotyping adds ~$10-20 but saves downstream expenses. Payers like CMS reimburse pooled high-risk tests—expansion could follow. (00123-4/fulltext)) 9/ Globally, this scales screening. WHO aims to vaccinate 90% of girls by 2030 and screen 70% of women—genotyping optimizes limited resources in low-resource areas. Roche and BD are pushing assays in Europe/Asia; U.S. traction could accelerate. 10/ What's next? Expect ASCCP or USPSTF reviews incorporating genotyping by 2027-2028. Labs like Quest and Labcorp are piloting extended panels. If Huh's vision sticks, "HPV positive" becomes obsolete—replaced by actionable type-specific intel. Track Contemporary OB/GYN for updates.

Key numbers

(contemporaryobgyn.net) 1/ HPV testing has transformed cervical cancer screening, but a new review in Contemporary OB/GYN pushes for a big upgrade: extended genotyping.
Instead of just "HPV positive" or "negative," labs would report specific genotypes like HPV-16 or 18.
There are over 200 HPV types, but only about 14 are high-risk for cervical cancer.
HPV-16 and 18 cause ~70% of cases worldwide, per WHO data.

What happens next

This builds on ASCCP guidelines, which already emphasize "equal management for equal risk." Genotyping data could refine that further.
Clinicians could skip colposcopy for low-risk singles (e.g., HPV-53) but act fast on HPV-16/18 doubles.
Poor implementation could confuse providers and delay care.

Sources

contemporaryobgyn.net

Quick answers

What happened in HPV extended genotyping gains traction?

A Contemporary OB/GYN review argues that reporting individual HPV genotypes could let clinicians tailor cervical screening beyond a simple positive/negative result. The authors say persistence of the same HPV type and ASCCP’s “equal management for equal risk” framework could be refined by extended genotyping data. If adopted, labs may face more selective cytology triage and will need clearer reporting and staff education. (contemporaryobgyn.net)

Why does HPV extended genotyping gains traction matter?

1/ HPV testing has transformed cervical cancer screening, but a new review in Contemporary OB/GYN pushes for a big upgrade: extended genotyping. Instead of just "HPV positive" or "negative," labs would report specific genotypes like HPV-16 or 18. This lets doctors tailor follow-up care more precisely. 2/ Why does this matter? There are over 200 HPV types, but only about 14 are high-risk for cervical cancer. HPV-16 and 18 cause ~70% of cases worldwide, per WHO data. Most infections clear naturally within 1-2 years, but persistent high-risk types drive precancerous changes. Current tests lump them together—genotyping splits them out. 3/ The review, by Dr. Warner Huh (UAB) and colleagues, argues genotyping reveals risk nuances. For example, persistent HPV-16 signals higher danger than a one-off HPV-51 detection. This builds on ASCCP guidelines, which already emphasize "equal management for equal risk." Genotyping data could refine that further. 4/ Take persistence: If the same genotype shows up in repeat tests, cancer risk climbs. Huh's team notes studies showing women with persistent HPV-16 have 100-200x higher risk of CIN3+ (precancer) vs. cleared infections. A simple positive/negative misses this—genotyping tracks the exact type over time. 5/ Real-world example: BD Onclarity, an FDA-approved test, already reports 14 high-risk types individually. Roche's cobas HPV test does 12, grouping some. The review spotlights these as models. Clinicians could skip colposcopy for low-risk singles (e.g., HPV-53) but act fast on HPV-16/18 doubles. 6/ Labs aren't ready yet. Adoption means shifting from pooled results to granular reports. Huh et al. warn of challenges: selective cytology triage (only for certain types), clearer result formatting, and staff training. Poor implementation could confuse providers and delay care. 7/ Guidelines are key. ASCCP's 2019 update prioritizes risk-based management over rigid rules. Genotyping fits perfectly—e.g., 4% immediate colposcopy risk for HPV-16/18+ vs. 1% for others at same cytology level, per management consortium data. Future updates might mandate it. 8/ Evidence is building. A 2023 study in The Lancet Oncology found genotyping cut unnecessary colposcopies by 20-30% without missing cancers. Cost? Tests run $40-60 now; genotyping adds ~$10-20 but saves downstream expenses. Payers like CMS reimburse pooled high-risk tests—expansion could follow. (00123-4/fulltext)) 9/ Globally, this scales screening. WHO aims to vaccinate 90% of girls by 2030 and screen 70% of women—genotyping optimizes limited resources in low-resource areas. Roche and BD are pushing assays in Europe/Asia; U.S. traction could accelerate. 10/ What's next? Expect ASCCP or USPSTF reviews incorporating genotyping by 2027-2028. Labs like Quest and Labcorp are piloting extended panels. If Huh's vision sticks, "HPV positive" becomes obsolete—replaced by actionable type-specific intel. Track Contemporary OB/GYN for updates.